Litcius/Paper detail

Suitability of external controls for drug evaluation in Duchenne muscular dystrophy

Nathalie Goemans, James Signorovitch, Gautam Sajeev, Zhiwen Yao, Heather Gordish‐Dressman, Craig M. McDonald, Krista Vandenborne, Debra Miller, Susan J. Ward, Eugenio Mercuri, for the investigators from PRO-DMD-01 Study, CINRG DNHS, ImagingDMD, and the DMD Italian Group

2020Neurology34 citationsDOIOpen Access PDF

Abstract

OBJECTIVE: To evaluate the suitability of real-world data (RWD) and natural history data (NHD) for use as external controls in drug evaluations for ambulatory Duchenne muscular dystrophy (DMD). METHODS: The consistency of changes in the 6-minute walk distance (Δ6MWD) was assessed across multiple clinical trial placebo arms and sources of NHD/RWD. Six placebo arms reporting 48-week Δ6MWD were identified via literature review and represented 4 sets of inclusion/exclusion criteria (n = 383 patients in total). Five sources of RWD/NHD were contributed by Universitaire Ziekenhuizen Leuven, DMD Italian Group, The Cooperative International Neuromuscular Research Group, ImagingDMD, and the PRO-DMD-01 study (n = 430 patients, in total). Mean Δ6MWD was compared between each placebo arm and RWD/NHD source after subjecting the latter to the inclusion/exclusion criteria of the trial for baseline age, ambulatory function, and steroid use. Baseline covariate adjustment was investigated in a subset of patients with available data. RESULTS: Analyses included ∼1,200 patient-years of follow-up. Differences in mean Δ6MWD between trial placebo arms and RWD/NHD cohorts ranged from -19.4 m (i.e., better outcomes in RWD/NHD) to 19.5 m (i.e., worse outcomes in RWD/NHD) and were not statistically significant before or after covariate adjustment. CONCLUSIONS: We found that Δ6MWD was consistent between placebo arms and RWD/NHD subjected to equivalent inclusion/exclusion criteria. No evidence for systematic bias was detected. These findings are encouraging for the use of RWD/NHD to augment, or possibly replace, placebo controls in DMD trials. Multi-institution collaboration through the Collaborative Trajectory Analysis Project rendered this study feasible.

Topics & Concepts

Duchenne muscular dystrophyMuscular dystrophyMedicineDrugPhysical medicine and rehabilitationPhysical therapyInternal medicinePharmacologyMuscle Physiology and DisordersAdipose Tissue and MetabolismMuscle metabolism and nutrition